Despite many efforts to address the disparities, the underrepresentation of gender, racial, and ethnic minorities in clinical trials remains a problem and undermines the efficacy of treatments on minorities. This paper focuses on the trial site selection task and proposes FRAMM, a deep reinforcement learning framework for fair trial site selection. We focus on addressing two real-world challenges that affect fair trial sites selection: the data modalities are often not complete for many potential trial sites, and the site selection needs to simultaneously optimize for both enrollment and diversity since the problem is necessarily a trade-off between the two with the only possible way to increase diversity post-selection being through limiting enrollment via caps. To address the missing data challenge, FRAMM has a modality encoder with a masked cross-attention mechanism for handling missing data, bypassing data imputation and the need for complete data in training. To handle the need for making efficient trade-offs, FRAMM uses deep reinforcement learning with a specifically designed reward function that simultaneously optimizes for both enrollment and fairness. We evaluate FRAMM using 4,392 real-world clinical trials ranging from 2016 to 2021 and show that FRAMM outperforms the leading baseline in enrollment-only settings while also achieving large gains in diversity. Specifically, it is able to produce a 9% improvement in diversity with similar enrollment levels over the leading baselines. That improved diversity is further manifested in achieving up to a 14% increase in Hispanic enrollment, 27% increase in Black enrollment, and 60% increase in Asian enrollment compared to selecting sites with an enrollment-only model.

We present the design and operation of tadpole-mimetic robots prepared for a study of the parenting behaviors of poison frogs, which pair bond and raise their offspring. The mission of these robots is to convince poison frog parents that they are tadpoles, which need to be fed. Tadpoles indicate this need, at least in part, by wriggling with a characteristic frequency and amplitude. While the study is in progress, preliminary indications are that the TadBots have passed their test, at least for father frogs. We discuss the design and operational requirements for producing convincing TadBots and provide some details of the study design and plans for future work.

Covenant Eyes is not the only tech firm to play on these concerns, however. California-based X3watch, for example, offers a similar tracking and reporting feature, albeit one that works by creating a categorised list of the sites users visit that is then shared with their accountability partners. 'This is an opportunity to know and be known,' the X3watch website argues. 'Whether your chosen partner is a friend or a spouse, or you've come across explicit activity on your children's devices, the true goal is liberation that blossoms from open and honest relationships with others who are dedicated to your well-being.' An annual subscription to X3watch is currently priced at $70 (£54) per year.